Skip to content
DE

DihexaExperimental peptidomimetic

Dihexa is an angiotensin-IV-derived experimental compound discussed in cognition research. Its public reputation runs ahead of a clinical evidence base.

What is Dihexa?

Dihexa is an experimental angiotensin-IV-derived compound discussed in cognition research. Human clinical benefit is not established by the evidence assessed here.

How it works

A proposed mechanism involves growth-factor signalling, particularly HGF/c-Met, and nerve-cell connections. Two papers related to this mechanistic foundation have retraction records. 5 6

Effects studied

Learning and memory

Animal-task findings do not establish improved human memory or daily function. Retracted papers cannot serve as dependable support for a clinical claim. 1 5 6

Evidence: Preclinical literature with material retractions

What does the evidence show?

Two PubMed retraction records were independently checked for this draft. They concern work underlying the proposed HGF/c-Met mechanism. The remaining retained references have not received a full clinical audit.

The biological proposal

Dihexa has been investigated in relation to growth-factor signalling and the formation of connections between nerve cells. A proposed interaction with the HGF/c-Met pathway attracted interest because such signalling can influence cell behaviour. It does not follow that stimulating the pathway would improve human memory safely.

What animal tasks measure

A rodent’s performance in a maze is a controlled experimental outcome. Human memory, attention and everyday functioning involve different tasks and sources of variation. Translating between them requires clinical trials, including a way to identify adverse effects that may not appear in a short animal experiment. 1

Why publication status matters

PubMed records confirm retractions of two papers related to the proposed HGF/c-Met mechanism. Retracted work should not be presented as dependable support. A complete review should establish which claims depend on it and which, if any, have independent replication. This draft does not reproduce numerical efficacy claims from those papers. 5 6

What remains unknown in humans

There is no human benefit established by the material assessed for this introduction. This describes the limits of the evidence reviewed here. It does not mean every possible biological effect has been disproved. “Research chemical” sales do not resolve questions about toxicology, identity, long-term effects or a lawful clinical product pathway.

Safety & status

Human toxicology, long-term effects and product identity remain unresolved. Research-chemical sales are not a safety assessment.

Country and product status

This introduction describes the molecule and its research context. Product availability, approved indications and eligibility in Germany and Switzerland require a current local product check; they are not established by an overseas study or an online listing.

Frequently asked questions

What changes when a paper is retracted?

Its findings should not be treated as reliable evidence. Claims dependent on it need independent support. 5 6

Is human cognitive enhancement established?

No. The assessed material does not establish a human benefit, regardless of how plausible a proposed pathway sounds.

Further reading

Concept illustration for Dihexa.GuideDihexa: missing human data and retracted foundational studiesDihexa is marketed as an experimental compound for memory and thinking. What preclinical research shows and which safety questions remain open.Read the article

Sources

This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.

  1. Dihexa: paper 10.1124/jpet.112.199497 Research reference · Retained archive reference; not independently checked for this draft.
  2. Retracted paper: HGF/c-Met and procognitive effects (2014) Research reference · Original paper retracted; retraction status independently confirmed in PubMed. Do not use as reliable efficacy evidence.
  3. Dihexa: www.fda.gov reference Reference or product information · Retained archive reference; not independently checked for this draft.
  4. Dihexa: pmc.ncbi.nlm.nih.gov reference Research reference · Retained archive reference; not independently checked for this draft.
  5. PubMed retraction notice: angiotensin IV analogues and HGF/Met (2012 paper) Retraction notice · PubMed retraction record independently checked, 27 October 2026. This confirms publication status, not a full audit of the research programme.
  6. PubMed retraction notice: procognitive and synaptogenic effects through HGF/c-Met (2014 paper) Retraction notice · PubMed retraction record independently checked, 27 October 2026. This confirms publication status, not a full audit of the research programme.
  7. Dihexa: retained correction or related research lead Research reference · Retained archive reference; not independently checked for this draft.
  8. Dihexa: retained correction or related research lead Research reference · Retained archive reference; not independently checked for this draft.
  9. Dihexa: retained correction or related research lead Research reference · Retained archive reference; not independently checked for this draft.
  10. Dihexa: retained correction or related research lead Research reference · Retained archive reference; not independently checked for this draft.
  11. Dihexa: retained correction or related research lead Research reference · Retained archive reference; not independently checked for this draft.
Research provenance

This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.